STOK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Stoke Therapeutics Inc (STOK) is not a strong buy for a beginner, long-term investor at this time. While the company has promising long-term catalysts, such as its Phase 3 EMPEROR trial for zorevunersen and positive analyst sentiment, the lack of recent news, weak financial performance, and neutral trading sentiment suggest holding off for now. Additionally, technical indicators and options data do not strongly support an immediate buy decision.
The technical indicators show mixed signals. The MACD histogram is positive at 0.105, indicating slight bullish momentum, but it is contracting. The RSI is neutral at 44.445, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is trading near its pivot level (35.674) with resistance at 36.937 and support at 34.411, suggesting limited upside potential in the short term.
Analysts have raised price targets recently, with Canaccord and Guggenheim setting targets at $60, citing the potential of zorevunersen as a disease-modifying therapy for Dravet syndrome.
The company's lead drug candidate, zorevunersen, has shown promising clinical data and could address a significant unmet medical need.
Financial performance in Q4 2025 was weak, with revenue dropping by 93.80% YoY and a net loss of -$57.93M.
Options data reflects bearish sentiment, with a high Put-Call ratio and low implied volatility percentile.
No recent news or significant insider or hedge fund activity to indicate strong near-term interest.
In Q4 2025, revenue dropped significantly by 93.80% YoY to $1.402M. However, net income improved to -$57.93M (up 452.70% YoY), and EPS increased to -0.98 (up 444.44% YoY). Gross margin remained at 100%. Despite some improvement in net income and EPS, the company's financials remain weak overall.
Analysts are optimistic about the stock's long-term potential, with multiple firms raising price targets and maintaining Buy or Outperform ratings. The highest price target is $60, driven by the potential of zorevunersen and its projected $2.5B global peak sales. However, the timeline for key milestones extends to mid-2027, making it a longer-term play.
